Testing effectiveness (Phase 2)Study completedNCT00047216What this trial is testingTipifarnib in Treating Patients With Recurrent Bladder CancerWho this might be right forBladder Cancer University Health Network, Toronto
Early research (Phase 1)Ended earlyNCT04187872What this trial is testingLITT and Pembrolizumab in Recurrent Brain MetastasisWho this might be right forMelanomaNon-small Cell Lung Carcinoma (NSCLC)Renal Cell Carcinoma (RCC)+12 more University of Florida 10
Testing effectiveness (Phase 2)Ended earlyNCT00089128What this trial is testingGemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder CancerWho this might be right forBladder Cancer Medical University of South Carolina 16
Not applicableStudy completedNCT02700464What this trial is testingThe Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell CarcinomaWho this might be right forBladder Cancer Nucleix Ltd. 680
Large-scale testing (Phase 3)Study completedNCT00003814What this trial is testingEflornithine in Treating Patients With Bladder CancerWho this might be right forBladder Cancer National Cancer Institute (NCI) 450
Testing effectiveness (Phase 2)UnknownNCT02740426What this trial is testingProphylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma PatientsWho this might be right forUpper Tract Urothelial CarcinomaBladder Recurrence Peking University First Hospital 200
Testing effectiveness (Phase 2)WithdrawnNCT01639521What this trial is testingGemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial CancerWho this might be right forAnterior Urethral CancerLocalized Transitional Cell Cancer of the Renal Pelvis and UreterPosterior Urethral Cancer+7 more University of Southern California
Not applicableStudy completedNCT00900276What this trial is testingBiomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy ParticipantsWho this might be right forBladder CancerKidney CancerTransitional Cell Cancer of the Renal Pelvis and Ureter+1 more Wake Forest University Health Sciences 5
Testing effectiveness (Phase 2)Study completedNCT00478361What this trial is testingGemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney FunctionWho this might be right forDistal Urethral CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterProximal Urethral Cancer+8 more M.D. Anderson Cancer Center 40
Testing effectiveness (Phase 2)Study completedNCT03513952What this trial is testingAtezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial CarcinomaWho this might be right forAdvanced Bladder Urothelial CarcinomaAdvanced Ureter Urothelial CarcinomaMetastatic Bladder Urothelial Carcinoma+21 more National Cancer Institute (NCI) 47
Testing effectiveness (Phase 2)Study completedNCT00888615What this trial is testingElesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerWho this might be right forFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous Adenocarcinoma+15 more GOG Foundation 58
Early research (Phase 1)Active Not RecruitingNCT04514484What this trial is testingTesting the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVWho this might be right forAdvanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular Carcinoma+60 more National Cancer Institute (NCI) 8
Testing effectiveness (Phase 2)Study completedNCT00407485What this trial is testingVEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the UrotheliumWho this might be right forAdenocarcinoma of the BladderDistal Urethral CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and Ureter+10 more National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT03237780What this trial is testingAtezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial CancerWho this might be right forLocally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma+21 more National Cancer Institute (NCI) 72
Testing effectiveness (Phase 2)Study completedNCT00004223What this trial is testingDocetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder CancerWho this might be right forBladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer Eastern Cooperative Oncology Group
Testing effectiveness (Phase 2)UnknownNCT05895864What this trial is testingUtidelone Treated for the Recurrent or Metastatic Urothelial CarcinomaWho this might be right forMetastatic Urothelial Carcinoma Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 34
Testing effectiveness (Phase 2)Ended earlyNCT01118351What this trial is testingSunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder CancerWho this might be right forRecurrent Bladder CancerTransitional Cell Carcinoma of the Bladder Case Comprehensive Cancer Center 19
Early research (Phase 1)Study completedNCT00003167What this trial is testingGene Therapy in Treating Patients With Advanced Bladder CancerWho this might be right forRecurrent Bladder CancerStage I Bladder CancerStage II Bladder Cancer+3 more National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Study completedNCT00112671What this trial is testingSorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary TractWho this might be right forMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and Ureter+4 more National Cancer Institute (NCI) 17
Early research (Phase 1)WithdrawnNCT05259397What this trial is testingPF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)Who this might be right forBladder Cancer Pfizer